
|Slideshows|February 2, 2017
Antipsychotic Augmentation vs Monotherapy in Schizophrenia
Author(s)Brian Miller, MD, PhD, MPH
To augment or not to augment? That is the question.
Advertisement
View the slides in PDF format. Also see: Antipsychotics and Breast Cancer Risk.
Newsletter
Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.
Advertisement
Advertisement
Advertisement
Trending on Psychiatric Times
1
December in Review: Updates on the Psychiatric Treatment Pipeline
2
Misguided Values of AI Companies and the Consequences for Patients
3
Research Recap From the European College of Neuropsychopharmacology Congress
4
Southern California Psychiatry: Review of New Agents in Schizophrenia and Dementia
5




